Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas,while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 μg | 5 days | $ 465.00 | |
50 μg | 5 days | $ 1,400.00 | |
500 μg | 5 days | $ 7,400.00 | |
1 mg | 5 days | $ 11,090.00 |
Description | Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas,while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
Species | Human |
Expression System | Human Cells |
Tag | N-Twin strep-Flag |
Accession Number | P56856-2 |
Synonyms | Claudin 18.2, CLDN18, Claudin-18, CLDN18.2, Claudin-18.2 |
Amino Acid | Met1-Ala200 |
Construction | Recombinant Human CLDN18.2 is produced by our Mammalian expression system and the target gene encoding Met1-Ala200 is expressed with a Twin strep, Flag tag at the N-terminus. |
Protein Purity | Greater than 70% as determined by reducing SDS-PAGE. Greater than 70% as determined by SEC-HPLC. |
Molecular Weight | 18-22 kDa, reducing conditions |
Endotoxin | Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
Formulation | Supplied as a 0.2 μm filtered solution of 50mM HEPES, 150mM NaCl, 0.06% DDM, 0.012% CHS, 10% Glycerol, pH 7.5. |
Stability & Storage |
Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
Shipping |
The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below. |
Research Background | Claudin-18 (CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. Human CLDN18.2 is highly expressed in a signifcant proportion of gastric and pancreatic adenocarcinomas,while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by eforts to target CLDN18.2 via naked antibody and CAR-T modalities. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
Claudin-18.2 Protein, Human, Recombinant (Twin strep & Flag) Claudin 18.2 CLDN18 CLDN 18 Claudin-18 CLDN18.2 CLDN-18 Claudin-18.2 recombinant recombinant-proteins proteins protein